Last reviewed · How we verify
Optimized neoantigen synthetic long peptide vaccine
Optimized neoantigen synthetic long peptide vaccine is a Biologic drug developed by Washington University School of Medicine. It is currently in Phase 1 development.
At a glance
| Generic name | Optimized neoantigen synthetic long peptide vaccine |
|---|---|
| Sponsor | Washington University School of Medicine |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Optimized neoantigen synthetic long peptide vaccine CI brief — competitive landscape report
- Optimized neoantigen synthetic long peptide vaccine updates RSS · CI watch RSS
- Washington University School of Medicine portfolio CI
Frequently asked questions about Optimized neoantigen synthetic long peptide vaccine
What is Optimized neoantigen synthetic long peptide vaccine?
Optimized neoantigen synthetic long peptide vaccine is a Biologic drug developed by Washington University School of Medicine.
Who makes Optimized neoantigen synthetic long peptide vaccine?
Optimized neoantigen synthetic long peptide vaccine is developed by Washington University School of Medicine (see full Washington University School of Medicine pipeline at /company/washington-university-school-of-medicine).
What development phase is Optimized neoantigen synthetic long peptide vaccine in?
Optimized neoantigen synthetic long peptide vaccine is in Phase 1.